Theralase Files Dosimetry Fibre Optic Cage Patent Application

Toronto, Ontario – June 22, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has filed a US patent for its proprietary Dosimetry Fibre Optic Cage (“DFOC”) technology.

DFOC technology allows Theralase to precisely monitor and remotely control laser light energy delivered to hollow organs, such as the bladder, when undergoing treatment with Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”).

The patent application is entitled, “Fiber Optic-Based Photodynamic Treatment Delivery and Irradiance Monitoring System and has been licenced to Theralase under a royalty agreement with Princess Margaret Cancer Centre, University Health Network (“UHN”).”

The current methodology planned for the Phase Ib clinical study for NMIBC involves:

 Intravesical installation of a sterile water based solution of TLD-1433 via catheter into the bladder of a patient

 Allowing the solution of TLD-1433 to absorb into any resident bladder cancer tumours for approximately sixty minutes

 Voiding the bladder and flushing the bladder twice with sterile water to remove any excess TLD-1433 solution not absorbed by bladder tumours

 Admitting the patient into the operating room and administrating a general anesthetic

 Insertion of a rigid cystoscope into the urethra of a patient

 Filling the bladder with sterile water to provide shape to the bladder

 Inserting the DFOC technology into the bladder via the cystoscope’s working channel

 Once resident in the bladder, the DFOC is deployed (like an umbrella) to strategically place optical detectors at twelve predetermined locations in the bladder to monitor and remotely control the amount of laser light delivered, providing a uniform distribution of laser light to the bladder wall

Dr. Lothar Lilge, Staff Scientist at UHN and inventor of the DFOC technology stated that, “The purpose of this research is to determine if we can deliver a uniform distribution of TLD-1433 solution to the bladder lesions and a uniform distribution of laser light to the bladder wall. If so, there should be a uniform activation of TLD-1433 absorbed by the cancerous lesions providing a safer, more tolerable and ultimately more effective destruction of bladder tumours than previously achieved. This hypothesis will be tested clinically in a Phase Ib clinical study for NMIBC to commence pending Investigational Testing Authorization (“ITA”) approval by Health Canada.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “The Company is a strong supporter of Dr. Lilge’s research at UHN. Dr. Lilge’s latest invention is focused on precisely controlling the amount of laser light received by the bladder wall and should increase the safety, tolerability and efficacy of the TLD-1433 treatments in the destruction of bladder cancer.”

About Theralase Technologies Inc. 

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed

laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo

Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at and .

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information: 

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225